曲妥珠-话题@MedSci

#曲妥珠#

132篇内容 | 1548人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1648203, encodeId=30831648203ff, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=JAMA Oncol：伊匹单抗 vs FOLFOX联合纳武单抗和曲妥珠单抗治疗ERBB2阳性胃食管腺癌, objectType=article, longId=730595, objectId=f470e305957c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f470e305957c, replyNumber=0, likeNumber=42, createdTime=2023-06-07, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f470e305957c, moduleTitle=JAMA Oncol：伊匹单抗 vs FOLFOX联合纳武单抗和曲妥珠单抗治疗ERBB2阳性胃食管腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f470e305957c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648196, encodeId=92fb1648196f4, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Clin Cancer Res：中肿袁中玉教授团队SYSUCC-002研究证实HR+HER2+转移性乳腺癌患者一线曲妥珠单抗+内分泌治疗非劣效于曲妥珠单抗+化疗, objectType=article, longId=293509, objectId=872a29350972, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=872a29350972, replyNumber=0, likeNumber=40, createdTime=2022-12-02, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=872a29350972, moduleTitle=Clin Cancer Res：中肿袁中玉教授团队SYSUCC-002研究证实HR+HER2+转移性乳腺癌患者一线曲妥珠单抗+内分泌治疗非劣效于曲妥珠单抗+化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=872a29350972)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648199, encodeId=b7251648199a7, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=JAMA Oncol：仿制药HD201在ERBB2阳性乳腺癌中的疗效堪比曲妥珠单抗！, objectType=article, longId=300545, objectId=1df2300545a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1df2300545a4, replyNumber=0, likeNumber=46, createdTime=2022-07-24, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1df2300545a4, moduleTitle=JAMA Oncol：仿制药HD201在ERBB2阳性乳腺癌中的疗效堪比曲妥珠单抗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1df2300545a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648201, encodeId=033a16482013c, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=European Radiology：CMRI对曲妥珠单抗辅助治疗乳腺癌患者的左房重构评价, objectType=article, longId=723578, objectId=b1cfe23578e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1cfe23578e6, replyNumber=0, likeNumber=48, createdTime=2022-05-05, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1cfe23578e6, moduleTitle=European Radiology：CMRI对曲妥珠单抗辅助治疗乳腺癌患者的左房重构评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1cfe23578e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648204, encodeId=55ed16482042d, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=JAMA Oncol：阿特珠单抗、多西他赛、曲妥珠单抗和帕妥珠单抗新辅助治疗ERBB2阳性早期乳腺癌的效果, objectType=article, longId=732001, objectId=e4e7e32001b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4e7e32001b1, replyNumber=0, likeNumber=51, createdTime=2023-05-21, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4e7e32001b1, moduleTitle=JAMA Oncol：阿特珠单抗、多西他赛、曲妥珠单抗和帕妥珠单抗新辅助治疗ERBB2阳性早期乳腺癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4e7e32001b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648197, encodeId=2563164819eb5, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=BMC Cancer：曲妥珠单抗和氟维司群联合治疗HR+/HER2+转移性乳腺癌患者的疗效和安全性, objectType=article, longId=293700, objectId=baae293e00d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=baae293e00d8, replyNumber=0, likeNumber=54, createdTime=2022-02-22, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=baae293e00d8, moduleTitle=BMC Cancer：曲妥珠单抗和氟维司群联合治疗HR+/HER2+转移性乳腺癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=baae293e00d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648194, encodeId=b46d164819486, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=J Clin Oncol：T-DM1+帕妥珠单抗 vs 紫杉类+曲妥珠单抗+帕妥珠单抗治疗高危HER2+早期乳腺癌患者的疗效和安全性：III期临床研究KAITLIN, objectType=article, longId=265037, objectId=970226503ec6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=970226503ec6, replyNumber=0, likeNumber=50, createdTime=2022-07-30, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=970226503ec6, moduleTitle=J Clin Oncol：T-DM1+帕妥珠单抗 vs 紫杉类+曲妥珠单抗+帕妥珠单抗治疗高危HER2+早期乳腺癌患者的疗效和安全性：III期临床研究KAITLIN, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=970226503ec6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648195, encodeId=b0201648195bd, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Eur Heart J：BBs和ACEI/ARBs用于预防乳腺癌患者因蒽环类药物或曲妥珠单抗引起的左心室功能障碍, objectType=article, longId=292762, objectId=e405292e62f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e405292e62f8, replyNumber=0, likeNumber=41, createdTime=2022-04-12, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e405292e62f8, moduleTitle=Eur Heart J：BBs和ACEI/ARBs用于预防乳腺癌患者因蒽环类药物或曲妥珠单抗引起的左心室功能障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e405292e62f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648200, encodeId=660b164820035, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Oncologist: HER2阳性胃癌既往曲妥珠单抗治疗进展后继续曲妥珠单抗联合伊立替康治疗并不能增加生存获益, objectType=article, longId=301447, objectId=d0c230144eb9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0c230144eb9, replyNumber=0, likeNumber=44, createdTime=2022-09-15, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0c230144eb9, moduleTitle=Oncologist: HER2阳性胃癌既往曲妥珠单抗治疗进展后继续曲妥珠单抗联合伊立替康治疗并不能增加生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0c230144eb9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648198, encodeId=5abb16481986f, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Ann Oncol：Tucatinib（图卡替尼）或安慰剂联合曲妥珠单抗+卡培他滨治疗经治晚期HER2+乳腺癌患者的疗效, objectType=article, longId=295100, objectId=fc8c295100d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc8c295100d4, replyNumber=0, likeNumber=51, createdTime=2022-12-05, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc8c295100d4, moduleTitle=Ann Oncol：Tucatinib（图卡替尼）或安慰剂联合曲妥珠单抗+卡培他滨治疗经治晚期HER2+乳腺癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc8c295100d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648187, encodeId=7bc1164818e94, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Br J Dermatol：曲妥珠单抗加局部皮质类固醇可有效且安全的治疗中度至重度特应性皮炎, objectType=article, longId=215845, objectId=09762158451c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09762158451c, replyNumber=0, likeNumber=56, createdTime=2022-04-19, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09762158451c, moduleTitle=Br J Dermatol：曲妥珠单抗加局部皮质类固醇可有效且安全的治疗中度至重度特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09762158451c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648202, encodeId=b416164820269, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Lancet Oncol：曲妥珠单抗+帕妥珠单抗±紫杉醇降级治疗HER2+/HR-早期乳腺癌, objectType=article, longId=724611, objectId=8841e2461153, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8841e2461153, replyNumber=0, likeNumber=48, createdTime=2022-05-22, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8841e2461153, moduleTitle=Lancet Oncol：曲妥珠单抗+帕妥珠单抗±紫杉醇降级治疗HER2+/HR-早期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8841e2461153)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648191, encodeId=81b116481916f, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Eur J Cancer：HER2阳性早期可手术乳腺癌患者中，术前曲妥珠单抗联合依维莫司的疗效和预测标志物探索, objectType=article, longId=220088, objectId=133b22008853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=133b22008853, replyNumber=0, likeNumber=42, createdTime=2021-12-24, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=133b22008853, moduleTitle=Eur J Cancer：HER2阳性早期可手术乳腺癌患者中，术前曲妥珠单抗联合依维莫司的疗效和预测标志物探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=133b22008853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648180, encodeId=6a70164818035, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=乳腺癌术后曲妥珠单抗治疗时长应该超过一年吗？, objectType=article, longId=213819, objectId=d73021381943, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d73021381943, replyNumber=0, likeNumber=45, createdTime=2022-04-21, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d73021381943, moduleTitle=乳腺癌术后曲妥珠单抗治疗时长应该超过一年吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d73021381943)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648188, encodeId=8119164818845, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=NEJM：曲妥珠ADC T-DXd用于HER2过表达的NSCLC的疗效与安全性（DESTINY-Lung01研究）, objectType=article, longId=217405, objectId=0fe821e405f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fe821e405f8, replyNumber=0, likeNumber=0, createdTime=2021-12-09, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fe821e405f8, moduleTitle=NEJM：曲妥珠ADC T-DXd用于HER2过表达的NSCLC的疗效与安全性（DESTINY-Lung01研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fe821e405f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648192, encodeId=fc581648192a9, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Clin Cancer Res：曲妥珠单抗联合内分泌或化疗作为HR+HER2+转移性乳腺癌的一线治疗的疗效对比, objectType=article, longId=220934, objectId=1c3f22093403, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c3f22093403, replyNumber=0, likeNumber=54, createdTime=2022-01-16, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c3f22093403, moduleTitle=Clin Cancer Res：曲妥珠单抗联合内分泌或化疗作为HR+HER2+转移性乳腺癌的一线治疗的疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c3f22093403)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648186, encodeId=d30d16481860e, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Lancet Oncol：meta分析显示化疗联合曲妥珠单抗对HER2阳性乳腺癌患者，能够显著降低复发和死亡风险, objectType=article, longId=215483, objectId=b69b21548371, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b69b21548371, replyNumber=0, likeNumber=53, createdTime=2021-08-12, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b69b21548371, moduleTitle=Lancet Oncol：meta分析显示化疗联合曲妥珠单抗对HER2阳性乳腺癌患者，能够显著降低复发和死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b69b21548371)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648193, encodeId=71bb16481931c, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Eur J Cancer：HER2阳性早期可手术乳腺癌患者中，术前曲妥珠单抗联合依维莫司的疗效和预测标志物探索, objectType=article, longId=221293, objectId=c4e6221293db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4e6221293db, replyNumber=0, likeNumber=35, createdTime=2022-09-03, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4e6221293db, moduleTitle=Eur J Cancer：HER2阳性早期可手术乳腺癌患者中，术前曲妥珠单抗联合依维莫司的疗效和预测标志物探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4e6221293db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648185, encodeId=5a2816481858b, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Lancet Oncol：帕妥珠单抗+曲妥珠单抗治疗HER2阳性转移性胆道癌的疗效和安全性, objectType=article, longId=215273, objectId=4e602152e3e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e602152e3e8, replyNumber=0, likeNumber=58, createdTime=2021-09-30, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e602152e3e8, moduleTitle=Lancet Oncol：帕妥珠单抗+曲妥珠单抗治疗HER2阳性转移性胆道癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e602152e3e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648184, encodeId=b47a1648184bf, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Eur J Cancer：拉帕替尼和曲妥珠单抗同步治疗HER2+乳腺癌可的预后, objectType=article, longId=214775, objectId=19d2214e7562, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19d2214e7562, replyNumber=0, likeNumber=41, createdTime=2021-11-22, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19d2214e7562, moduleTitle=Eur J Cancer：拉帕替尼和曲妥珠单抗同步治疗HER2+乳腺癌可的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19d2214e7562)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

曲妥珠

2020-05-29

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

JAMA Oncol：伊匹单抗 vs FOLFOX联合纳武单抗和曲妥珠单抗治疗ERBB2阳性胃食管腺癌

2023-06-07

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Clin Cancer Res：中肿袁中玉教授团队SYSUCC-002研究证实HR+HER2+转移性乳腺癌患者一线曲妥珠单抗+内分泌治疗非劣效于曲妥珠单抗+化疗

2022-12-02

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

JAMA Oncol：仿制药HD201在ERBB2阳性乳腺癌中的疗效堪比曲妥珠单抗！

2022-07-24

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

European Radiology：CMRI对曲妥珠单抗辅助治疗乳腺癌患者的左房重构评价

2022-05-05

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

JAMA Oncol：阿特珠单抗、多西他赛、曲妥珠单抗和帕妥珠单抗新辅助治疗ERBB2阳性早期乳腺癌的效果

2023-05-21

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

BMC Cancer：曲妥珠单抗和氟维司群联合治疗HR+/HER2+转移性乳腺癌患者的疗效和安全性

2022-02-22

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

J Clin Oncol：T-DM1+帕妥珠单抗 vs 紫杉类+曲妥珠单抗+帕妥珠单抗治疗高危HER2+早期乳腺癌患者的疗效和安全性：III期临床研究KAITLIN

2022-07-30

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Eur Heart J：BBs和ACEI/ARBs用于预防乳腺癌患者因蒽环类药物或曲妥珠单抗引起的左心室功能障碍

2022-04-12

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Oncologist: HER2阳性胃癌既往曲妥珠单抗治疗进展后继续曲妥珠单抗联合伊立替康治疗并不能增加生存获益

2022-09-15

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Ann Oncol：Tucatinib（图卡替尼）或安慰剂联合曲妥珠单抗+卡培他滨治疗经治晚期HER2+乳腺癌患者的疗效

2022-12-05

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Br J Dermatol：曲妥珠单抗加局部皮质类固醇可有效且安全的治疗中度至重度特应性皮炎

2022-04-19

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Lancet Oncol：曲妥珠单抗+帕妥珠单抗±紫杉醇降级治疗HER2+/HR-早期乳腺癌

2022-05-22

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Eur J Cancer：HER2阳性早期可手术乳腺癌患者中，术前曲妥珠单抗联合依维莫司的疗效和预测标志物探索

2021-12-24

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

乳腺癌术后曲妥珠单抗治疗时长应该超过一年吗？

2022-04-21

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

NEJM：曲妥珠ADC T-DXd用于HER2过表达的NSCLC的疗效与安全性（DESTINY-Lung01研究）

2021-12-09

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Clin Cancer Res：曲妥珠单抗联合内分泌或化疗作为HR+HER2+转移性乳腺癌的一线治疗的疗效对比

2022-01-16

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Lancet Oncol：meta分析显示化疗联合曲妥珠单抗对HER2阳性乳腺癌患者，能够显著降低复发和死亡风险

2021-08-12

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Eur J Cancer：HER2阳性早期可手术乳腺癌患者中，术前曲妥珠单抗联合依维莫司的疗效和预测标志物探索

2022-09-03

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Lancet Oncol：帕妥珠单抗+曲妥珠单抗治疗HER2阳性转移性胆道癌的疗效和安全性

2021-09-30

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Eur J Cancer：拉帕替尼和曲妥珠单抗同步治疗HER2+乳腺癌可的预后

2021-11-22

科室
- - 订阅+
  - 更多科室
工具
服务